12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Autologous CD34+ cells: Phase I/II data

The open-label, Italian Phase I/II TIGET-MLD trial in 3 evaluable pre-symptomatic patients with evidence of late infantile MLD showed that IV infusions of autologous CD34+ cells transfected with a lentiviral vector encoding functional ARSA protein led...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >